FDA Inspection 1165379 - Juno Therapeutics Inc, a subsidiary of Bristol-Myers Squibb - March 18, 2022

FDA Inspection 1165379 for Juno Therapeutics Inc, a subsidiary of Bristol-Myers Squibb on March 18, 2022. Classification: No Action Indicated (NAI).

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA Inspection 1165379 for Juno Therapeutics Inc, a subsidiary of Bristol-Myers Squibb on March 18, 2022. Classification: No Action Indicated (NAI).

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Juno Therapeutics Inc, a subsidiary of Bristol-Myers Squibb

Inspection Date

March 18, 2022

Product Type

Biologics

Office

Center for Biologics Evaluation and Research

ID: 1cb15bd3-1666-4ed4-9c26-58a4519a63c5

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox